Table 1.
Study cohort (96 people with cystic fibrosis): demographic and clinical data.
| Patient characteristics | n (%) |
|---|---|
| Age group (years) | |
| < 13 | 7 (7.3) |
| 13–< 18 | 2 (2.1) |
| 18–< 25 | 30 (31.3) |
| 25–< 30 | 14 (14.6) |
| ≥ 30 | 43 (44.7) |
| Gender | |
| Female | 47 (49.0) |
| Male | 49 (51.0) |
| cftr mutation | |
| p.F508del homozygote | 53 (55.2) |
| p.F508del heterozygote | 33 (34.4) |
| Other mutation | 10 (10.4) |
| Pancreas status | |
| Pancreatic sufficiency | 8 (8.3) |
| Pancreatic insufficiency | 88 (91.7) |
| Body-mass index▲ (kg/m2) | |
| Underweight (< 18.5) | 22 (22.9) |
| Reference value (18.5–24.9) | 63 (65.6) |
| Overweight/Obesity (> 24.9) | 11 (11.5) |
| Lung function (Forced Expiratory Volume in one second, %) | |
| < 40 | 23 (24.0) |
| 40–70 | 54 (56.3) |
| > 70 | 19 (19.7) |
| Chronic antibiotic therapy (inhaled and/or oral) | |
| Azithromycin | 53 (55.2) |
| Tobramycin | 19 (19.8) |
| Colistin | 49 (51.0) |
| Aztreonam | 8 (8.3) |
| Oral antibiotic therapy (one month before) | |
| Yes | 39 (40.6) |
| No | 57 (59.4) |
| Corticosteroids (inhaled and/or oral) | |
| Yes | 73 (76.0) |
| No | 23 (24.0) |
| Diabetes | |
| Yes | 38 (39.6) |
| No | 58 (60.4) |
| CFTR modulators (ivacaftor, lumacaftor) | |
| Yes | 29 (30.2) |
| No | 62 (64.6) |
| Change during study | 5 (5.2) |
| Leeds status (Pseudomonas aeruginosa colonisation) | |
| Never | 5 (5.2) |
| Free | 21 (21.9) |
| Intermittent | 11 (11.5) |
| Chronic | 59 (61.4) |